Gilead Sciences (GILD) Tops Q1 EPS by 31c

Gilead Sciences (NASDAQ: GILD) reported Q1 EPS of $2.12, $0.31 better than the analyst estimate of $1.81. Revenue for the quarter came in at $6.6 billion versus the consensus estimate of $6.28 billion.

GUIDANCE:

Gilead Sciences sees Q2 2022 EPS of $6.20-$6.70, versus the consensus of $6.50. Gilead Sciences sees Q2 2022 revenue of $23.8-24.3 billion, versus the consensus of $24.48 billion.

For earnings history and earnings-related data on Gilead Sciences (GILD) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• Corpay agrees to $100M FTC settlement over marketing practices
• Redburn upgrades Southwest, stays bullish on Delta and United